Quantum Genomics - Firibastat Phase III to start by end of the year
The company recently reported positive feedback from the FDA for its Phase III programme design for firibastat. There will be two studies required for approval: one focused on efficacy and one on safety. The efficacy study, QGC001/3QG1, will be a three-month 500-patient study comparing firibastat to placebo in difficult-to-treat or resistant hypertension patients who are already on treatments from two or three anti-hypertensive classes. Enrolment is expected to begin by the end of this year with data in H221. The safety study will enrol 750 patients, with 650 staying on the drug for six months and 100 staying on it for a year.Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.